Rekvina Labs (526075)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Current price of ₹4.50 is at the bottom of the 52-week range vs high of ₹46.65, so much pessimism is already embedded in the price.
• Market cap of only ₹3 crore means a modest absolute turnaround in earnings could have a large per-share impact.
• Reported ROE of 324.21%, though likely distorted by a tiny equity base, highlights there is no large equity drag on future returns if operations revive.
• As a listed pharma entity, it retains a BSE/NSE listing and a sector identity that could attract restructuring or reverse-merger interest.

Concerns

• Zero sales and zero net profit in the latest quarter means there is no operating business currently generating value.
• Profit growth of -500% and a Piotroski F-Score of 2/9 signal severe deterioration and poor fundamentals.
• Book value, P/B, debt/equity, and promoter holding are all N/A, making it impossible to establish any margin of safety.
• ROCE of 0.00% and no dividend yield provide no evidence of productive capital or return to shareholders.

AI Analysis

At first glance, this is not a business I can analyze; it is a quote. Rekvina Labs trades at ₹4.50 with a market cap of just ₹3 crore. The latest quarter shows sales of ₹0 crore and net profit of ₹0 crore. A company with no revenue and no earnings cannot have a meaningful P/E; the printed 0.00 is an accounting artifact, not value. Profit growth is -500%, sales growth is 0%, and ROCE is 0.00%. The Piotroski F-Score of 2/9 only confirms what I see: deteriorating fundamentals and weak financial health. The 52-week range of ₹4.50 to ₹46.65 means the stock has fallen over 90%, but a falling price is not automatically a bargain. Graham taught us to quantify margin of safety; here, book value is N/A, debt/equity is N/A, and even promoter holding is N/A. I cannot calculate a price-to-book cushion or assess who is in charge. The 324% ROE looks spectacular, but no equity base is reported, so it is likely a distortion from a very small or negative equity, not operating excellence. There is no dividend yield to reward patience. In Buffett's terms, there is no moat, no identifiable earnings power, no predictable cash flow. It could be a shell, a speculative trading counter, or a recovery story that lacks any disclosed evidence. If something real emerges—revenue, positive earnings, a clean balance sheet—I will reconsider. Until then, this is a pass. In the world of value investing, 'too hard' is an acceptable answer. The numbers do not propose a valuation; they propose a mystery. I would rather miss the gain than risk my capital on an undeclared position.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer